pharma · Generalized Myasthenia Gravis · Chronic inflammatory demyelinating polyneuropathy (CIDP)
Argenx
argenx
Argenx trial registry — 32 ClinicalTrials.gov studies with program phase, status, and indication context.
Company details
- Status
- Public
- HQ
- 33 Arch Street, Suite 3201, Boston, MA 02110, US
- Founded
- 2008
- Employees
- 2,179
- Programs
- 32
- Drugs
- 16
- Patents
- 0
Argenx clinical trials
Registry index of 32 ClinicalTrials.gov studies linked to Argenx programs — each row shows trial ID, program name, phase, status, and indication.
Argenx trial registry — 32 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Argenx.
-
ARGX-119-2303 — Phase 2
Clinical update -
ARGX-117-2402 — Phase 3
Clinical update -
ARGX-117-2301 — Phase 2
Clinical update -
ARGX-113-2405 — Phase 1
Clinical update -
ARGX-113-2315 — Phase 3
Clinical update -
ARGX-113-2007 — Phase 3
Clinical update -
ARGX-117-2003 — Phase 2
Clinical update -
ARGX-113-2009 — Phase 3
Clinical update
Trial registry
-
CTIS ↗ -
CTIS ↗ -
CTIS ↗ -
CTIS ↗ -
CTIS ↗ -
CTIS ↗ -
CTIS ↗ -
CTIS ↗ -
CTIS ↗ -
CTIS ↗ - 2024-510932-36-00CTIS ↗
Vyvgart 20 mg/mL concentrate for solution for infusion
Generalized Myasthenia Gravis (gMG)
-
CTIS ↗ -
CTIS ↗ - 2024-511796-15-00CTIS ↗
ARGX-113-2308
Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
-
CTIS ↗ -
CTIS ↗ - 2024-513854-31-00CTIS ↗
Vyvgart 20 mg/mL concentrate for solution for infusion
Generalized Myasthenia Gravis
-
CTIS ↗ -
CTIS ↗ -
CTIS ↗ -
CTIS ↗ -
CTIS ↗ -
CTIS ↗ -
CTIS ↗ -
CTIS ↗ -
CTIS ↗ -
CTIS ↗ - 2025-521524-30-00CTIS ↗
A study to assess the safety of ARGX-121 in Healthy Adult Participants
Healthy volunteers
- 2025-522492-28-00CTIS ↗
ARGX-117, ARGX-113
AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗